S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(0.97%) $80.00
Gas
(5.73%) $2.64
Gold
(1.44%) $2 419.80
Silver
(6.36%) $31.78
Platinum
(2.18%) $1 094.70
USD/EUR
(-0.02%) $0.920
USD/NOK
(-0.18%) $10.68
USD/GBP
(-0.27%) $0.787
USD/RUB
(0.19%) $91.05

Aktualne aktualizacje dla ProKidney Corp. [PROK]

Giełda: NASDAQ Capital Market Sektor: Healthcare Branża: Biotechnology
BUY
100.00%
return 5.98%
SELL
0.00%
return 5.90%
Ostatnio aktualizowano17 geg. 2024 @ 23:00

6.99% $ 4.06

KUPNO 138350 min ago

@ $1.280

Wydano: 13 vas. 2024 @ 16:30


Zwrot: 216.80%


Poprzedni sygnał: vas. 12 - 21:52


Poprzedni sygnał: Sprzedaż


Zwrot: -3.76 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract...

Stats
Dzisiejszy wolumen 546 394
Średni wolumen 774 563
Kapitalizacja rynkowa 939.54M
EPS $0 ( 2024-05-09 )
Następna data zysków ( $-0.220 ) 2024-08-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -7.11
ATR14 $0.00700 (0.17%)
Insider Trading
Date Person Action Amount type
2024-03-25 Control Empresarial De Capitales S.a. De C.v. Buy 30 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-22 Control Empresarial De Capitales S.a. De C.v. Buy 14 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-20 Control Empresarial De Capitales S.a. De C.v. Buy 33 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-14 Control Empresarial De Capitales S.a. De C.v. Buy 50 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
2024-03-13 Control Empresarial De Capitales S.a. De C.v. Buy 50 000 Class A Ordinary Shares (as defined in Exhibit 99.1 hereto)
INSIDER POWER
-30.35
Last 98 transactions
Buy: 21 980 380 | Sell: 30 162 499

Wolumen Korelacja

Długi: 0.28 (neutral)
Krótki: 0.36 (neutral)
Signal:(69.74) Neutral

ProKidney Corp. Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ProKidney Corp. Korelacja - Waluta/Towar

The country flag 0.32
( neutral )
The country flag 0.48
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.54
( weak negative )
The country flag -0.09
( neutral )

ProKidney Corp. Finanse

Annual 2023
Przychody: $0
Zysk brutto: $-3.17M (0.00 %)
EPS: $-0.570
FY 2023
Przychody: $0
Zysk brutto: $-3.17M (0.00 %)
EPS: $-0.570
FY 2022
Przychody: $0
Zysk brutto: $-3.04M (0.00 %)
EPS: $-2.41
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-0.296

Financial Reports:

No articles found.

ProKidney Corp. Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej